Eli Lilly Stock: Why the Weight-Loss Boom Is Just Beginning

Join Ross’s Patreon Community for exclusive content and LIVE events

https://www.patreon.com/cw/TheRealRossMandell?utm_campaign=creatorshare_creator

Is Eli Lilly stock still in the early stages of the weight-loss boom? In this episode of Going Public with Ross Mandell, Ross breaks down his bullish outlook on LLY stock and explains why Mounjaro and Zepbound could be just the beginning. Explore how diabetes treatments, obesity drugs, and the growing GLP-1 market fit into his investment thesis.

The discussion covers oral weight-loss treatments such as orforglipron, retatrutide’s clinical development, and Lilly’s plans to expand manufacturing and reach more patients worldwide. Ross examines the company’s earnings, revenue growth, and drug pipeline, explaining why he sees an opportunity extending beyond today’s blockbuster injections.

Ross also addresses Eli Lilly’s stock pullback, valuation, competition from Novo Nordisk and other drugmakers, and the execution risks investors should watch. Learn which developments he’s tracking—from clinical trial results and international expansion to production capacity and financial guidance—and why a strong business still needs to justify its stock price. Subscribe to Going Public for more stock market analysis, healthcare stocks, and emerging investment themes.

About Ross Mandell:

Ross Mandell is a former Wall Street professional, entrepreneur, author, and capital formation expert. On Going Public with Ross Mandell, Ross interviews athletes, entrepreneurs, investors, doctors, creators, and high performers about success, failure, reinvention, money, health, business, and what it takes to rebuild after adversity.

This content is for informational and educational purposes only and does not constitute financial or investment advice.

🔗 Links & Resources

📌 Book A Call With Ross

https://buy.stripe.com/9B64gydlh4dJfhXecP5Vu08

📲 Follow Ross Mandell on Instagram